After further evaluation, she was diagnosed with cholangiocarcinoma, or bile duct cancer, a rare and aggressive cancer that ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

Jazz Pharmaceuticals JAZZ will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for ...

The surgical treatment of mid-low rectal cancer poses greater technical challenges, and whether robotic surgery provides superior safety and efficacy compared to laparoscopic surgery remains ...

The following is a summary of "Intraoperative Ultrasound-Guided Breast-Conserving Surgery: A Performance Analysis On The ...

Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

Further subgroup analysis was performed with reference to the resection margins and the nodal status. As a reminder, in the ESPAC-4 trial, 60% of patients were found to have microscopically positive ...

NeoGenomics shares dropped 34% on April 29 after missing its Q1 revenue estimates. Check out why I view the stock price ...

Telix has been shocked by the US Food & Drug Administration's rejection of marketing approval for its brain cancer diagnostic ...

Q1 2025 Earnings Call Transcript April 30, 2025 Guardant Health, Inc. beats earnings expectations. Reported EPS is $-0.49, ...

Pfizer is facing some revenue pressures due to some higher Medicare discounts. Read more to see why I upgrade PFE stock from ...